PCSK9 inhibition to lower LDL-cholesterol and reduce cardiovascular risk: Great expectations
- Author(s): Waters, DD
- Hsue, PY
- et al.
Published Web Locationhttps://doi.org/10.1161/CIRCRESAHA.115.306493
© 2015 American Heart Association, Inc. New clinical trials with the proprotein convertase subtilisin- kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab show that these drugs not only lower lowdensity lipoprotein cholesterol (LDL-C) profoundly, but also seem to reduce cardiovascular events, although the number of events and duration of follow-up are limited. Larger trials are underway to confirm these findings and to document safety.
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.